Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients

ConclusionOur results might provide guidance in cases with heavily pre-treated patients, where alternatives are limited. Carboplatin and bevacizumab treatment should be weighed against best supportive care, current non-platinum therapies and experimental treatment. cfDNA seems to offer prognostic insight.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research